Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

NCT07501169 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG: Sacituzumab Tirumotecan and Anlotinib

Sponsor

Sichuan University

Collaborators

[object Object]
[object Object]